HCW Biologics Inc. (NASDAQ:HCWB) stock is rallying after securing a $4 million private placement to fund its clinical pipeline. Read the full market breakdown.
HCW Biologics said its proprietary multi-cytokine fusion protein reagent, HCW9206, offers a cost-effective way to generate higher-function CAR-T cells for immunotherapy.
Wondering how the US markets performed one hour before the close of the markets on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
